Young Paul J, Bellomo Rinaldo, Al-Fares Abdulrahman, Antognini David Gc, Arabi Yaseen M, Ashraf Muhammad Sheharyar, Bagshaw Sean M, Brown Alastair J, Buabbas Sarah, Campbell Lewis, Chen Jonathan M, Freebairn Ross C, Fujii Tomoko, Hasan Mohd Shahnaz, Jain Aditi, Lai Nai An, Lakhey Sanjay, Partlin Matthew Mac, Marment Sam, McCullough James P A, Nichol Alistair D, Ramanan Mahesh, Regmi Ashim, Saxena Manoj, Seppelt Ian, Shima Nozomu, Twardowski Pawel, White Kyle C, Lamontagne François
Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.
Medical Research Institute of New Zealand, Wellington, New Zealand.
Crit Care Resusc. 2025 Feb 27;27(1):100095. doi: 10.1016/j.ccrj.2024.12.001. eCollection 2025 Mar.
This study aimed to evaluate intensive care doctors' views about a large-scale pragmatic minimum mean arterial pressure (MAP) targets trial and their attitudes and beliefs about minimum MAP targets in different clinical scenarios.
An online survey was conducted.
An online survey was distributed to intensive care doctors in sites participating in a large-scale international randomised clinical trial evaluating oxygen therapy targets in 15 countries and to additional intensive care clinicians from Canada.
Outcomes included the expressed level of support for a large pragmatic trial to evaluate minimum MAP targets in critically ill adults and stated current practice and acceptability of minimum MAP for specific scenarios.
The response rate to our survey for respondents who work in sites participating in the mega randomised registry trial research program was 265 out of 701 (37.8%), with an additional 56 out of 256 (21.8%) responses obtained from a direct email containing a link to the survey sent to intensive care clinicians in Canada. A total of 309 of 321 respondents (96.3%) were supportive, in principle, of conducting a very large pragmatic trial to evaluate MAP targets in intensive care unit patients receiving noradrenaline. The commonest response in all scenarios was to agree that the optimal minimum MAP target was uncertain. In all scenarios, except for active bleeding, the most common reported minimum MAP target was 65 mmHg; for patients who were actively bleeding, the most common reported target was 60 mmHg.
Our data suggest that intensive care clinicians are broadly supportive of a large-scale pragmatic minimum MAP targets in intensive care unit patients receiving noradrenaline.
本研究旨在评估重症监护医生对一项大规模实用最低平均动脉压(MAP)目标试验的看法,以及他们在不同临床场景下对最低MAP目标的态度和信念。
进行了一项在线调查。
向参与一项在15个国家评估氧疗目标的大规模国际随机临床试验的各点的重症监护医生,以及来自加拿大的其他重症监护临床医生发放了在线调查问卷。
结果包括对一项评估危重症成人最低MAP目标的大型实用试验的支持程度,以及当前针对特定场景的最低MAP的实践情况和可接受性。
在参与大型随机登记试验研究项目各点工作的受访者中,我们调查的回复率为701人中有265人回复(37.8%),另外通过直接电子邮件向加拿大的重症监护临床医生发送包含调查问卷链接的邮件,又获得了256人中的56人回复(21.8%)。在321名受访者中,共有309人(96.3%)原则上支持开展一项非常大型的实用试验,以评估接受去甲肾上腺素治疗的重症监护病房患者的MAP目标。在所有场景中最常见的回答是同意最佳最低MAP目标不确定。在所有场景中,除了活动性出血外,报告的最常见最低MAP目标是65 mmHg;对于活动性出血的患者,报告的最常见目标是60 mmHg。
我们的数据表明,重症监护临床医生普遍支持对接受去甲肾上腺素治疗的重症监护病房患者设定大规模实用最低MAP目标。